JotieP schreef op 24 februari 2022 12:15:
Attached an overview of the financials 2017 - 2021 + forecast 2022.
I'm extremely worried about the SG&A that keeps increasing and increasing, even at a higher pace than the sales.
considering a 16-18% gross margin, BCART has a huge issue. increasing to 25-30% is progress, but with this progress year on year, it will take multiple years to become profitable.
I'm also worried about the sloppy figures in the financials. ref to f.ex. page 7 from below link, where product sales revenue + service revenue is not equal to total revenue. Or they are missing a line, or they are wrongly calculating... investors.biocartis.com/sites/default...
i noticed a couple of these inconsistencies and that's also making me more cautious.
unfortunately I didn't lower my position in the past year, and now i guess it's too late. it's already low now :-).
PS: they conveniently mentioned "operational cashflow" reduction of 9.5 - 13.5 M ... it looks like they would have just enough cash at end of 2022, but considering the other 2 cashflow-impacts, we will not reach end of 2022.
At the current stock price, convertibles will also not be converted into shares.
All hope is now on an acquisition for me. it could cover a part of my losses.